NHS Offers Lifeline Treatments for Rare Muscle Disease

Medicines watchdog NICE has approved two treatments, nusinersen and risdiplam, for patients with spinal muscular atrophy (SMA). This decision means that from Thursday, any patient in England, Wales, or Northern Ireland who could benefit will have access to these drugs through the NHS. SMA is a serious genetic disorder that severely impacts muscle function, breathing, and swallowing. Without treatment, particularly for severe Type 1 SMA, life expectancy is drastically reduced.

These treatments represent a significant advancement in care. Prof James Palmer stated that these therapies offer hope for children to reach milestones previously unimaginable, like attending school. About 1,150 under-18s have SMA in England, with an estimated 70 babies born with the condition annually in the UK. One parent shared how nusinersen transformed her son Ezra's life, preventing his death and allowing him to attend mainstream school.

The availability of these drugs follows price agreements between NHS England and manufacturers. Nusinersen is given via spinal injection, while risdiplam is an oral medication. Experts from NICE confirm the drugs offer substantial, life-changing benefits, including longer life, maintained independence, and reduced hospital care. Separately, research is ongoing into newborn screening for SMA, with an NHS evaluation planned for October to potentially integrate it into routine care.